[stock_market_widget type=”card” template=”basic2″ assets=”ALVO” realtime=”true” api=”yahoo-finance”]
Modern medicine leans more and more on biologic drugs, which are complex treatments grown inside living cells rather than mixed together in a chemical plant. Because they are made from living systems, no two batches are ever perfectly identical, which shapes both how they are produced and how they are regulated. They are used against cancer, autoimmune conditions, and rare blood disorders, and they tend to carry high price tags. In the U.S., biologics make up only about 5% of prescriptions, yet they account for more than half of the country’s total spending on medicines.
When the patents protecting these drugs run out, other manufacturers can produce near-copies called biosimilars, which regulators clear for sale only after confirming there are no clinically meaningful differences from the original. The draw is cost, since a biosimilar usually reaches the market at a discount of anywhere from 10% to 40% below the branded version. Regulators credit these products with roughly $56 billion in U.S. savings over the past decade. Even so, the field is young: the Food and Drug Administration has approved fewer than 80 biosimilars, and their share of the biologics market still sits below 20%. That gap is precisely what pulls developers in, because every aging blockbuster represents a large pool of sales waiting to be contested.
That backdrop frames an agreement announced today. Alvotech (NASDAQ: ALVO) (STO: ALVO-SDB), a company that develops and manufactures biosimilar medicines, entered a licensing and commercialization deal with Lotus Pharmaceutical Co., Ltd. (TWSE: 1795), a specialty drugmaker based in Taiwan. The arrangement covers two of Alvotech’s candidates across the U.S. and selected Asian markets.
The first candidate, known internally as AVT34, is a proposed biosimilar to Imfinzi, a cancer immunotherapy sold by AstraZeneca PLC (NASDAQ: AZN). Imfinzi produced about $6.06 billion in sales in 2025. The second, AVT87, is a proposed biosimilar to Hemlibra, a hemophilia treatment from Roche Holding AG (SIX: ROG). Hemlibra brought in close to $6.0 billion (CHF 4.8 billion) last year. Both reference products, in other words, sit firmly in blockbuster territory, which is why even a modest share of either market can be worth pursuing.
In a partnership like this one, Alvotech generally takes charge of development and manufacturing, while the local partner handles regulatory filings, marketing, and distribution within its territories. Lotus already sells and distributes other Alvotech products in parts of Asia, so the new deal builds on an existing relationship rather than opening a cold one. The two companies did not disclose financial terms, which means details such as upfront payments, development milestones, and royalty rates are not yet public.
For a smaller developer, agreements of this sort serve a very practical purpose. They add candidates to the pipeline, stretch a company’s reach into new countries, and shift much of the cost and risk of selling in each market onto a partner with local expertise. For the partner receiving the license, the appeal runs the other way, since it gains a ready to sell product without shouldering the years of laboratory work behind it. They can also generate income over time through milestone payments and a share of eventual sales, which helps pay for the long and expensive process of carrying a biosimilar through testing and approval. Neither AVT34 nor AVT87 is on the market yet, so their value rests on winning regulatory clearances and, after that, on real demand.
What the agreement really points to is steady movement in a business built on patience. Biosimilars take years to develop and run into crowded competition the moment they launch, yet the underlying arithmetic keeps drawing companies back, because branded biologics worth more than $170 billion in annual sales are set to lose patent protection by 2030. Adding cancer and hemophilia candidates to its lineup gives Alvotech two more entries in a slow contest whose reward is a share of medicines that patients and health systems are eager to afford.
